Table 1.
Demographic, clinical, and treatment characteristics of the cohort, by the degree of hepatic fibrosis based on the AST-to-platelet ratio index
| APRI <1.5 No significant fibrosis (n=19,281) |
APRI ≥1.5 Significant fibrosis (n=1,027) |
P | |
|---|---|---|---|
| Age, years | 34 (29–40) | 34 (30–39) | <0.001 |
| Male sex | 7,771 (40) | 621 (59) | <0.001 |
| WHO clinical stage | |||
| 1 or 2 | 6,734 (35) | 180 (18) | <0.001 |
| 3 or 4 | 12,441 (65) | 846 (82) | |
| Body mass index | |||
| >25 | 1,679 (9) | 40 (4) | <0.001 |
| 18–25 | 11,868 (63) | 551 (56) | |
| <18 | 5,201 (28) | 402 (40) | |
| Tuberculosis | 2,899 (15) | 238 (23) | <0.001 |
| CD4+ count, cells/mm3 | |||
| >200 | 6,326 (34) | 146 (15) | |
| 100–200 | 6,024 (33) | 260 (27) | <0.001 |
| <100 | 6,089 (33) | 568 (58) | |
| ART regimen | |||
| NRTI | |||
| D4T+3TC | 6,962 (36) | 447 (44) | <0.001 |
| AZT+3TC | 5,702 (30) | 214 (21) | |
| TDF+XTC | 6,490 (34) | 360 (35) | |
| NNRTI | |||
| NVP | 13,528 (70) | 554 (54) | <0.001 |
| EFV | 5,753 (30) | 473 (46) | |
All values are median (IQR) or number (%).
Abbreviations: APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; WHO, World Health Organization; NRTI, nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleotide reverse transcriptase inhibitor; D4T, stavudine; 3TC, lamivudine; XTC, either lamivudine or emtricitabine; AZT, zidovudine; TDF, tenofovir; NVP, nevirapine; EFV, efavirenz; ART, antiretroviral therapy